Evidence Hub

The blocking effect of zinc on complement factor H in vitro: further proof by the hemolytic assay of Pilar Sánchez-Corral

K. Kerboua, Saadia Lasla, Maria-Hadjer Kerboua, Kamel Djennouhat

Journal of immunoassay & immunochemistry, 2023

1 citation

Abstract

Dear Editor, The only method that is available to study the control of alternative C3/C5convertase by the complement factor H (CFH) was developed by the team of Pilar Sánchez-Corral in 2003 using sheep erythrocytes. Nonetheless, we recall that the control of alternative C3/C5-convertase activity by CFH depends on the trimolecular complex formation of C3b-CFH-Factor I (FI) that itself depend on the binding capacity of CFH to cell membranes. Meanwhile, defective interactions at CFH–heparin sites reduce the CFH activity on surface-bound C3b, while the fluid phase activity continues to prevent C3/C5-convertase formation. On the other hand, Zn2+ that ranges between 2 and 15 μM in physiology, has the capacity to inhibit cell lysis induced by activated complement when its concentrations exceed 50 μM as initially described by Gotze et al. on red cells. The most relevant comprehensive mechanism of this hemolysis inhibition was deciphered by the team of Stephen J. Perkins who are shaping an emerging view based on the capacity of zinc to induce nonphysiologically complex between C3 molecules and complement factor H (CFH). Nevertheless, all these previous reports regarding Zn/CFH interaction were limited to purified systems using biophysical methods and fluid-phase degradation assays, and no study has yet addressed this question using Pilar Sánchez-Corral assay that uses sheep erythrocytes as a non-activator surface. To study CFH interaction with Zn2+, we have used two hemolytic assays…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free